NewAmsterdam Pharma Company N.V. (NAMS)
(Delayed Data from NSDQ)
$23.62 USD
+1.89 (8.70%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $23.64 +0.02 (0.08%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NAMS 23.62 +1.89(8.70%)
Will NAMS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NAMS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NAMS
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q2 Loss, Tops Revenue Estimates
Wall Street Analysts Predict a 132.5% Upside in NewAmsterdam Pharma Company N.V. (NAMS): Here's What You Should Know
NAMS: What are Zacks experts saying now?
Zacks Private Portfolio Services
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q1 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Other News for NAMS
Decoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT Insight
NewAmsterdam Pharma reports Q2 results
NewAmsterdam Pharma Co NV Reports Q2 2025 Earnings: EPS of -$0. ...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results | ...
NewAmsterdam Pharma reports Q2 revenue $19.145M vs $2.279M last year